UPDATE: Syros Pharmaceuticals (SYRS) PT Raised to $23 at Roth Capital

September 23, 2021 8:26 AM EDT
Get Alerts SYRS Hot Sheet
Price: $4.21 +3.44%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 18 | New: 16
Trade Now! 
Join SI Premium – FREE
(Updated - September 23, 2021 8:27 AM EDT)

Roth Capital analyst Zegneh Jallah raised the price target on Syros Pharmaceuticals (NASDAQ: SYRS) to $23.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "Monday, updated Phase 1 dose-escalation data for SY-5609 in heavilypretreated patients with solid tumors was presented at ESMO. Notably, 38% of patients achieved SD and tumor reductions up to 20%, which was encouraging since most had progressed on prior therapies. SY-5609 was best tolerated on a 7-day-on/7-day-off regimen, and Syros plans to use this regimen with chemo in Pancreatic Cancer, and with a BTK inhibitor in Mantle Cell Lymphoma. We've updated our model to reflect that, supporting our PT increase."


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Roth Capital